Background Interstitial lung disease (ILD) associated with Rheumatoid Arthritis (RA) has a poor prognosis. Treatments such as anti-TNF, have been implicated in the exacerbation of an ILD. Objectives Our objective is to evaluate and compare the evolution of ILD in patients with RA treated with Abatacept (ABA), Rituximab (RTX) and Tocilizumab (TCZ) after 1 year of treatment. Methods Retrospective multicentre study of patients with ILD and AR treated with ABA, RTX and TCZ at standard doses. The ILD was diagnosed by CT. The efficacy was evaluated whith the following measures: i) Dyspnea by modified scale of the Medical Research Council (mMRC); considering variations of 1 point. ii) Respiratory function tests; considering variations in FVC and DLCO ≥10%. iii) Imaging test (CT). Results We included 118 (72 women/46 men) patients, mean age of 62.27±10.55 years. The ILD had a median evolution of 12 12–37 months. The RA was ACPA+in 102 cases (86.4%). At diagnosis, the mean DLCO onset of biological treatment was 65.63±19.38. Table 1 shows the characteristics by subgroups. The Figure expresses the evolution in the cases available at 12 months. There is an improvement in CT in 36.4% of patients with ABA, 28.6% of patients with RTX and only 8.3% of patients with TCZ.Abstract THU0186 – Table 1 ABA RITU TCZ p AGE median years 65 (57–70) 64 (54,75–72) 60 (48–68,5) 0.187 SEX M/F 36/27 21/9 15/10 0490 SMOKER OR EX-SMOKER Si/No 25/38 13/17 11/14 0909 APCC+ 85,7 90 84 0776 BIOLOGICAL DMARD BEFORE% 44.4 30 60 0084 DLCO Onset 64.76±15.93 67.52±23.4142 65.58±22.700 0.854 CTUIP/OTHERS 29/34 14/16 11/14 0677 FVC at star 87.09±15.56 87.83±23.14 80.38±27.79 0.178 MONTHS OF EVOLUTION OF PNEUMONITIS 12 (12–36,75) 15 (5,75–37,75) 10 (3–10) 0875 *p significant <0,05 Conclusions There seems to be a trend towards a better radiological response in patients treated with RTX and ABA. It would be necessary prospective studies. Disclosure of Interest None declared